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Purpose: Due to the low rate of screening for prostate cancer in Japan, the incidence rates of cancer are high. We have established a 
prostate-specific antigen (PSA)-based screening system for prostate cancer in our region. We analyzed recent trends of clinical symptoms 
and prognosis of prostate cancer patients aged 55 to 69 years old in our institution. 
Methods: Between 2000 and 2007, 162 cases of prostate cancer in patients aged 55 to 69 years old were newly diagnosed. The 
study population was divided into 119 cases with high PSA without symptoms, 36 cases with urological symptoms, and 7 cases with 
systemic symptoms. We analyzed the clinical courses of the patients in each group. 
Results: The rate of localized disease was significantly higher in the PSA testing group than in the other groups. The median serum PSA 
levels were 1,600 ng/mL in the systemic symptom group, 13.3 ng/mL in the urological symptom group, and 7.1 ng/mL in the PSA testing 
group. The probability of nonrecurrence of the patients in the PSA testing group was significantly higher than in the other groups. 
Conclusions: The rate of prostate cancer patients diagnosed by PSA testing was relatively high in our institution. These patients have 
better prognosis than those with symptoms.
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INTRODUCTION
Prostate cancer is the most common form of cancer among 
men in Western countries, and the mortality rate of prostate 
cancer was high in the 1990s [1]. However, according to the lat-
est cancer registry in the USA, the mortality rate has decreased 
since 1992, and in 2004 showed a 34% decrease compared 
with 1990 [2]. Taking into consideration the recent high rate of 
prostate-specific antigen (PSA) testing in the USA among men 
aged 50 years or older, the decrease in cancer mortality may 
be due to the establishment of PSA-based screening systems 
and subsequent appropriate treatment for screening-detected 
prostate cancer.
 In Japan, the incidence rates of prostate cancer have in-
creased and are estimated to continue to do so in the near 
future. The number of patients with newly diagnosed prostate 
cancer will make this the second most common form of can-
cer among men in Japan following lung cancer [3]. The mor-
tality rate of prostate cancer will also increase in the future, 
and it has been predicted to reach 2.8 times higher in 2020 than 
that in 2000 [4]. One of the reasons for these prospects is that 
the rate of screening for prostate cancer in Japan is still very 
low compared with the USA and Western Europe. Screening 
systems for prostate cancer have not been established by the 
national government and depend on each municipal govern-
ment in Japan. Moreover, it is difficult to determine the results 
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 Clinical staging was determined in accordance with the 
unified TNM criteria based on the results of digital rectal ex-
amination, transrectal ultrasound, computed tomography, 
magnetic resonance imaging (MRI), and bone scan [7]. Path-
ological tumor grading was determined by transrectal biopsy 
before initiation of any treatment.
 The mean follow-up time was 37.1 months. Biochemical re-
currence was defined as two consecutive increases in serum 
PSA levels. Freedom from biochemical and/or clinical recur-
rence was calculated from the date of pathological diagnosis. 
Kaplan-Meier analysis was used for estimation of recurrence 
and cause-specific survival, and the significance of differenc-
es between each group was determined using the log-rank 
test. Other statistical assessments were performed using the 
χ2 and Fisher exact tests, and P<0.05 was considered statisti-
cally significant.
RESULTS
Age, clinical stage, Gleason score of prostate biopsy specimens, 
and serum PSA levels at diagnosis of the patients are presented 
in Table 1. The patients recruited into this study ranged in age 
from 55 to 69 years, and there were no significant differences 
in age between the three groups. All of the patients in the sys-
temic symptom group had distant and/or lymph node metas-
tases. The clinical stages of the patients in the urological symp-
tom group and in the PSA testing group were T1c and T2 for 24 
and 103 patients, T3 for 3 and 6, T4 for 3 and 3, and N1 and/or 
M1 for 6 and 7, respectively. The rate of localized disease was 
significantly higher in the PSA testing group than in the other 
groups. The median Gleason scores of biopsy specimens were 
as follows: systemic symptom group, 9; urological symptom 
group, 6.5; and PSA testing group, 6. The Gleason score of 
biopsy specimens in the PSA testing group was significantly 
lower than in the other groups. In terms of serum PSA level at 
diagnosis, as we set the PSA cutoff to 2.0 ng/mL in our screen-
of cancer screening correctly because the cancer registration 
systems of the various registries have not been standardized 
[5]. We have established a PSA-based screening system for 
prostate cancer by the municipal government in Kanazawa, 
Japan [6], which has been implemented in the region. To in-
vestigate the effectiveness and usefulness of our population-
based screening program, the present study was performed to 
analyze the clinical courses of prostate cancer patients aged 
55 to 69 years old in our institution.
MATERIALS AND METHODS
Since 2000, we have performed PSA-based screening for 
prostate cancer in men aged 55 to 69 years old [6]. Between 
2000 and 2007, 423 cases of prostate cancer were newly diag-
nosed in our institution, and 162 of these cases (38.3%) were 
patients aged 55 to 69 years old. One hundred of these 162 
cases (61.7%) were referred to our institution because of high 
PSA levels detected on PSA-based screening in the region. 
Nineteen cases (11.7%) were referred from general practitio-
ners because of high PSA levels without urological symptoms. 
Thirty-six cases (22.2%) had urological symptoms (including 
symptoms of benign prostatic hyperplasia), and 7 cases (4.3%) 
had systemic symptoms at the time of diagnosis. The study 
population was divided into 119 cases with high PSA without 
symptoms (PSA testing group), 36 cases with urological symp-
toms (urological symptom group), and 7 cases with systemic 
symptoms (systemic symptom group). We have followed-up 
the patients and analyzed the clinical courses of each group.
Table 1. Characteristics of the groups of patients divided by 
clinical symptoms
Variable
Systemic  
symptom
Urological  
symptom
PSA  
testing
No of patients 7 36 119
Median age (yr) 66 65.5 65
Clinical stage
   T1c, T2 0 24 103
   T3 0 3 6
   T4 0 3 3
   N1 and/or M1 7 6 7
Gleason score
   ≤6 0 18 70
   7 2 9 34
   8–10 5 9 15
Serum PSA (ng/mL)
   ≤4 0 1 15
   4.1–10 0 13 66
   10.1–20 0 7 15
   ≥20.1 7 15 23
PSA, prostate-specific antigen.
Table 2. Primary treatments for each group
Treatment
Systemic  
symptom
Urological  
symptom
PSA  
testing
Radical prostatectomy 0 15 48
High dose brachyterapy 0   8 37
Permanent implant 
   brachyterapy
0   0   6
External beam radiation 0   1   1
Primary androgen deprivation 7 12 21
Watchful waiting 0   0   5
HIFU 0   0   1
PSA, prostate-specific antigen; HIFU, high-intensity focused ultrasound.
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the prognosis of prostate cancer patients remains controver-
sial [8,9]. However, some recent studies indicated good prog-
nosis of prostate cancer patients in countries and regions with 
established mass screening systems [10,11]. The results of the 
Tyrol screening project indicated a 70% decrease in metastatic 
prostate cancer in the area following the introduction of free 
PSA testing, and the exposure rate was high at 86.6% [10].
 In Japan, as screening systems for prostate cancer have 
not been established by the national government and the 
awareness of the importance of PSA testing is very low among 
healthy people, the exposure rate is thought to be about 10% 
among men aged 50 years or older. Although screening for 
prostate cancer, including PSA testing, has been performed 
by the municipal governments and in “human dry-dock” 
programs in general hospitals since the 1990s, the rates of 
screening for candidates are different between municipal gov-
ernments and are especially very low in metropolitan areas. 
Recently, we established a PSA-based screening system for 
prostate cancer, which has been implemented in Kanazawa, 
Japan [6]. The rate of screening is about 20% for men aged 55 
to 69 years old in the city. Moreover, as general practitioners 
are aware of the importance of PSA testing, it is implemented 
in their male patients without urological symptoms. There-
fore, the rate of PSA testing in our region has increased above 
the average for Japan. In this study, we showed that 119 of 
162 patients (73.5%) aged 55 to 69 years old in our institution 
were identified by PSA testing. Although we cannot evaluate 
whether the rate is high because there have been no recent 
analyses of chief complaints in middle-aged patients diag-
nosed with prostate cancer, the rate of patients diagnosed by 
PSA testing may increase with the widespread adoption of 
PSA-based mass screening. 
ing [6], there were 15 patients with serum PSA levels under 4.0 
ng/mL. The median serum PSA levels were 1,600 ng/mL in the 
systemic symptom group, 13.3 in the urological group, and 7.1 
in the PSA testing group. The serum PSA levels at diagnosis in 
the PSA testing group were significantly lower than those in 
the other groups.
 Table 2 shows the variety of treatment methods used. All 
of the patients in the systemic symptom group were treated 
with primary androgen deprivation therapy. In contrast, 24 
of 36 patients (66.7%) in the urological symptom group and 
93 of 119 (78.2%) in the PSA testing group were treated with 
surgery and radiation. 
 Serum PSA levels could be obtained for all patients at a 
mean postdiagnosis follow-up of 37.1 months. Five patients 
(3.1%) died of prostate cancer, and clinical and/or biochemi-
cal recurrence occurred in 19 patients (11.7%). Cancer-specific 
survival rates for each group are shown in Fig. 1. The prob-
abilities of survival at 5 years were 98.2% and 96.3% for the 
PSA testing and urological symptom groups, respectively. In 
contrast, the corresponding percentage for the patients in the 
systemic symptom group was 40.0%; this difference was statis-
tically significant.
 Recurrence-free survival rates for each group are shown 
in Fig. 2. The probabilities of nonrecurrence at 5 years were 
91.6%, 70.8%, and 47.6% in PSA testing, urological symptom, 
and systemic symptom groups, respectively. The probability 
of non-recurrence in the PSA testing group was significantly 
higher than those in the other groups.
DISCUSSION
The effectiveness of PSA-based mass screening for improving 
Fig. 1. Kaplan-Meier plots of cancer-specific survival rates of pros-
tate cancer patients in prostate-specific antigen (PSA) testing, 
urological symptom, and systemic symptom groups. *P<0.01.
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Fig. 2. Kaplan-Meier plots of recurrence-free rates of prostate can-
cer patients in prostate-specific antigen (PSA) testing, urological 
symptom, and systemic symptom groups. *P<0.05, †P<0.01. 
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 We showed that the rate of patients with local disease in the 
PSA testing group was higher than those in the symptomatic 
groups. Moreover, the patients in the PSA testing group had a 
better prognosis. As mentioned in some recent reports [10,11], 
the mortality rate of prostate cancer may also decrease in the 
regions of Japan with established mass screening programs.
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